ES2168357T3 - Agonistas del receptor ep2 como agentes para disminuir la presion intraocular. - Google Patents

Agonistas del receptor ep2 como agentes para disminuir la presion intraocular.

Info

Publication number
ES2168357T3
ES2168357T3 ES95909222T ES95909222T ES2168357T3 ES 2168357 T3 ES2168357 T3 ES 2168357T3 ES 95909222 T ES95909222 T ES 95909222T ES 95909222 T ES95909222 T ES 95909222T ES 2168357 T3 ES2168357 T3 ES 2168357T3
Authority
ES
Spain
Prior art keywords
around
sub
link
carbon atoms
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95909222T
Other languages
English (en)
Inventor
David F Woodward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Sales LLC
Original Assignee
Allergan Sales LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Sales LLC filed Critical Allergan Sales LLC
Application granted granted Critical
Publication of ES2168357T3 publication Critical patent/ES2168357T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA INVENCION SE REFIERE A ( (MAS MENOS) ) TRANS- 2-[[]-4(()1HIDROXIHEXILO()) FENILO[]]-5-OXOCICLOPENTANOHEPTANOICACIDO, Y ESTER Y DERIVADOS INSATURADOS DEL MISMO, DERIVADOS DE PROSTAGLANDINA. EN CONCRETO, LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE FORMULA (I), EN DONDE LOS ENLACES ONDULADOS INDICAN LA CONFIGURACION {AL} O {BE}, EL ENLACE DISCONTINUO REPRESENTA O UN ENLACE UNICO O UNO DOBLE, EL CUAL PUEDE SER UN ENLACE DOBLE CIS O TRANS Y R ES UN GRUPO DE HIDROCARBURO SATURADO O INSATURADO ACICLICO QUE TIENE DE 1 A ALREDEDOR DE 20 ATOMOS DE CARBONO, O (()CH{SUB,2}()){SUB,M}R{SUB,1}- EN DONDE M ES DE 0-10, Y R{SUB,1} ES UN ANILLO ALIFATICO QUE TIENE DESDE ALREDEDOR DE 3 A ALREDEDOR DE 7 ATOMOS DE CARBONO, O UN ANILLO DE ARILO O HETEROARILO QUE TIENE DE ALREDEDOR DE 4 A ALREDEDOR DE 10 ATOMOS DE CARBONO Y EN DONDE EL HETEROATOMO SE SELECCIONA DEL GRUPO QUE CONSTA DE N, O Y S. LOS COMPUESTOS DE LA PRESENTE INVENCION SON POTENTES HIPOTENSORES OCULARES, Y SON PARTICULARMENTE UTILES PARA ELTRATAMIENTO DE GLAUCOMA.
ES95909222T 1994-01-19 1995-01-09 Agonistas del receptor ep2 como agentes para disminuir la presion intraocular. Expired - Lifetime ES2168357T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/183,682 US5462968A (en) 1994-01-19 1994-01-19 EP2 -receptor agonists as agents for lowering intraocular pressure

Publications (1)

Publication Number Publication Date
ES2168357T3 true ES2168357T3 (es) 2002-06-16

Family

ID=22673876

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95909222T Expired - Lifetime ES2168357T3 (es) 1994-01-19 1995-01-09 Agonistas del receptor ep2 como agentes para disminuir la presion intraocular.

Country Status (7)

Country Link
US (1) US5462968A (es)
EP (1) EP0789687B1 (es)
JP (2) JP4275194B2 (es)
AU (1) AU685591B2 (es)
DE (1) DE69524446T2 (es)
ES (1) ES2168357T3 (es)
WO (1) WO1995019964A1 (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2293325C (en) * 1997-05-09 2008-09-02 The Mount Sinai School Of Medicine Of The City University Of New York 8-iso-prostaglandins for glaucoma therapy
US6090847A (en) * 1997-11-21 2000-07-18 Allergan Sales, Inc. EP2 -receptor agonists as neuroprotective agents for the eye
US5877211A (en) * 1997-11-21 1999-03-02 Allergan EP2 receptor agonists as neuroprotective agents for the eye
EP1000619A3 (en) * 1998-06-23 2002-07-24 Pfizer Products Inc. Method for treating glaucoma
AU2211700A (en) 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Prostaglandin e agonists for treatment of glaucoma
CA2364948C (en) 1999-03-05 2011-04-26 Duke University C16 unsaturated fp-selective prostaglandins analogs
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20040254230A1 (en) * 2001-12-03 2004-12-16 Ogidigben Miller J. Method for treating ocular hypertension
AU2003209571A1 (en) * 2002-03-18 2003-09-29 Pfizer Products Inc. Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension
EP1513523A1 (en) * 2002-06-06 2005-03-16 Merck Frosst Canada & Co. 1,5-disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases
JP2006021998A (ja) * 2002-07-18 2006-01-26 Ono Pharmaceut Co Ltd Ｅｐ２アゴニストを有効成分とする月経困難症治療剤
CA2495917A1 (en) * 2002-08-28 2004-03-11 Merck Frosst Canada & Co. Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma
EP1563846B1 (en) 2002-10-10 2012-08-29 Ono Pharmaceutical Co., Ltd. Endogenous repair factor production promoters
WO2004037786A2 (en) * 2002-10-25 2004-05-06 Merck Frosst Canada & Co. 2-pyrrolidones as ep4 receptor agonists
CA2515631C (en) * 2003-02-11 2013-08-20 Allergan, Inc. 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure
EP1661580B1 (en) 2003-07-25 2014-01-08 Ono Pharmaceutical Co., Ltd. Remedy for cartilage-related diseases
US7745374B2 (en) 2003-08-05 2010-06-29 Oji Paper Co., Ltd. Thermal transfer receiving sheet, production method thereof and image forming method using the sheet
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
GB0329620D0 (en) * 2003-12-22 2004-01-28 Pharmagene Lab Ltd EP2 receptor agonists
WO2006043655A1 (ja) 2004-10-22 2006-04-27 Ono Pharmaceutical Co., Ltd. 吸入用医薬組成物
US7091231B2 (en) * 2004-12-10 2006-08-15 Allergan, Inc. 12-Aryl prostaglandin analogs
AU2006223514A1 (en) 2005-03-10 2006-09-21 Allergan, Inc. Substituted gamma lactams as therapeutic agents
US7674786B2 (en) * 2005-05-06 2010-03-09 Allergan, Inc. Therapeutic β-lactams
WO2006121822A1 (en) * 2005-05-06 2006-11-16 Allergan, Inc. USE OF β-LACTAMS FOR THE TREATMENTOF IBD AND GLAUCOMA
AU2006253356B2 (en) 2005-06-03 2011-12-01 Ono Pharmaceutical Co., Ltd. Agent for regeneration and/or protection of nerves
CA2648162C (en) * 2006-04-04 2016-02-02 Allergan, Inc. Prostaglandin analogues for the treatment of glaucoma or ocular hypertension
US20090016981A1 (en) 2006-05-03 2009-01-15 Allergan, Inc. Therapeutic compounds
US7439372B2 (en) * 2006-05-03 2008-10-21 Allergan, Inc. Therapeutic compounds
US7476755B2 (en) * 2006-05-04 2009-01-13 Allergan, Inc. Therapeutic compounds
US7491844B2 (en) 2006-05-04 2009-02-17 Allergan, Inc. Therapeutic cyclopentane derivatives
US7557095B2 (en) * 2006-05-12 2009-07-07 Allergan, Inc. Therapeutic compounds
US7547727B2 (en) * 2006-05-22 2009-06-16 Allergan, Inc. Therapeutic cyclopentane derivatives
US7498447B2 (en) 2006-05-24 2009-03-03 Allergan, Inc. Therapeutic compounds
US7550448B2 (en) 2006-05-24 2009-06-23 Allergan, Inc. Therapeutic compounds
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US9365485B2 (en) 2007-01-25 2016-06-14 Allergan, Inc. Substituted arylcyclopentenes as therapeutic agents
WO2008091818A1 (en) 2007-01-25 2008-07-31 Allergan, Inc. Substituted arylcyclopentenes as therapeutic agents
US8063033B2 (en) * 2008-01-18 2011-11-22 Allergan, Inc. Therapeutic beta-lactams
US7956051B2 (en) * 2008-01-24 2011-06-07 Allergan, Inc. Therapeutic amides and related compounds
US8633310B2 (en) * 2008-02-19 2014-01-21 Allergan, Inc. Therapeutic substituted lactams
US7964596B2 (en) * 2008-03-07 2011-06-21 Allergan, Inc. Therapeutic compounds
US20090233921A1 (en) * 2008-03-11 2009-09-17 Allergan, Inc. Therapeutic cyclopentane derivatives
US7960379B2 (en) * 2008-03-14 2011-06-14 Allergan, Inc. Therapeutic compounds
US7732443B2 (en) * 2008-03-18 2010-06-08 Yariv Donde Therapeutic substituted cyclopentanes
US8198318B2 (en) * 2008-03-18 2012-06-12 Allergen, Inc. Therapeutic amides
US7956055B2 (en) * 2008-03-25 2011-06-07 Allergan, Inc. Substituted gamma lactams as therapeutic agents
EP2297085B1 (en) * 2008-04-24 2019-03-20 Allergan, Inc. Substituted arylcyclopentenes as therapeutic agents
US7964634B2 (en) * 2008-04-24 2011-06-21 Allergan, Inc. Therapeutic compounds
AU2009239369B2 (en) * 2008-04-24 2014-03-06 Allergan, Inc. Substituted arylcyclopentenes as prostaglandin EP2 agonists
WO2009132088A1 (en) 2008-04-24 2009-10-29 Allergan, Inc. Substituted gamma lactams as therapeutic agents
CA2723894A1 (en) 2008-05-09 2009-11-12 Allergan, Inc. Therapeutic substituted hydantoins, and related compounds
EP2285782A2 (en) * 2008-05-09 2011-02-23 Allergan, Inc. Therapeutic n-aryl or n-heteroaryl pyrazolidine and pyrazolidinone derivatives
CA2728227A1 (en) * 2008-05-09 2009-11-12 Allergan, Inc. Therapeutic cyclopentane derivatives
US8569349B2 (en) * 2008-05-09 2013-10-29 Allergan, Inc. Therapeutic compounds
CA2724605A1 (en) * 2008-05-27 2009-12-03 Allergan, Inc. Prostaglandin prodrugs as hypotensive agents
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
US7985765B2 (en) 2008-08-20 2011-07-26 Allergan, Inc. Therapeutic substituted pyrroles
EP3828172A1 (en) 2009-05-01 2021-06-02 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
ES2733998T3 (es) 2012-10-29 2019-12-03 Cardio Incorporated Agente terapéutico específico de enfermedad pulmonar
US20140275160A1 (en) 2013-03-15 2014-09-18 Aerie Pharmaceuticals, Inc. Combination therapy
US9000032B2 (en) 2013-05-31 2015-04-07 Allergan, Inc. Substituted cyclopentenes as therapeutic agents
US9968716B2 (en) 2013-10-15 2018-05-15 Ono Pharmaceutical Co., Ltd. Drug-eluting stent graft
US9394273B2 (en) * 2014-05-15 2016-07-19 Allergan, Inc. Therapeutic prostaglandin receptor agonists
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
CN109640966A (zh) 2016-08-31 2019-04-16 爱瑞制药公司 眼用组合物
WO2018183911A1 (en) 2017-03-31 2018-10-04 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
US11427563B2 (en) 2018-09-14 2022-08-30 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
DE3220156C2 (de) * 1982-05-28 1990-01-25 Heida Houston Tex. Thurlow Mit Metallgriffen, insbesondere Edelstahlgriffen, versehenes Koch- und Bratgeschirr mit Deckel
EP1348437A3 (en) * 1988-09-06 2003-11-19 Pharmacia Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5034413A (en) * 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins

Also Published As

Publication number Publication date
AU685591B2 (en) 1998-01-22
WO1995019964A1 (en) 1995-07-27
EP0789687A1 (en) 1997-08-20
US5462968A (en) 1995-10-31
JPH09509652A (ja) 1997-09-30
AU1725795A (en) 1995-08-08
JP2008214351A (ja) 2008-09-18
JP4275194B2 (ja) 2009-06-10
DE69524446T2 (de) 2002-06-27
DE69524446D1 (de) 2002-01-17
EP0789687B1 (en) 2001-12-05

Similar Documents

Publication Publication Date Title
PY0125507A (es) Agonistas del receptor b3-adrenergico y usos de los mismos
ES2127946T3 (es) Antagonistas de neurocinina diazabiciclica.
ES2113368T3 (es) Antagonistas de serotonina.
RU2291860C3 (ru) Производные 2-оксо-1-пирролидина, способ их получения и применения
ES2164657T3 (es) Derivados aza-biciclicos puenteados como antagonistas de la sustancia p.
ES2164920T3 (es) Nuevos derivados heterociclicos y uso medicinal de los mismos.
ES2059491T3 (es) Derivados de indol con anillos condensados.
ES2121223T3 (es) Derivados de indol como antagonistas de tromboxano a2.
ES2094719T3 (es) Derivados de pirazol y herbicidas que los contienen.
PE20020720A1 (es) Derivados benzimidazol y piridilimidazol como ligandos para receptores gabaa
ES2053508T3 (es) Compuestos de acidos 3-pirrolidinil-tio-1-azabiciclo(3.2.0)hept-2-eno-2-carboxilicos.
ES2064700T3 (es) Derivados de adenosina con actividad farmaceutica como antihipertensivos.
ES2098123T3 (es) Nuevos analogos de vitamina d.
ES2106616T3 (es) Derivados de 11,21-bisfenilo-19-nor-pregnanos.
ES2117400T3 (es) Inhibidores de metaloproteinasas.
FR2387968A1 (fr) Derives soufres du 1,2,4-triazole, utilisables comme additifs de lubrifiants
AR009413A1 (es) Un compuesto, el cual es un derivado de distamicina benzoheterociclico, su utilizacion, un procedimiento para producirlo y una composicionfarmaceutica que lo comprende
EA200300716A1 (ru) Гетероциклилалкилиндольные или -азаиндольные соединения в качестве лиганд 5-гидрокситриптамина-6
ES2123873T3 (es) Pirrolocarbazol.
ES2107522T3 (es) 2-descarboxil-2-aminoalquil-prostaglandinas como agentes hipotensivos oculares.
ES2151168T3 (es) N-(2,4-dioxo-2,3,4,5-tetrahidro-1h-1,5-benzodiazepin-3-il)-3-amidas.
ES2084339T3 (es) Tetrahidropiridinas e hidroxipiperidinas sustituidas utiles como agentes para el sistema nervioso central.
PE69398A1 (es) Antagonistas de receptor de benzoxazinona dopamina d4
ES2110260T3 (es) Androstenonas.
ES2062202T3 (es) Derivado del indol.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 789687

Country of ref document: ES